IOVA - Iovance Biotherapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Iovance Biotherapeutics, Inc.

999 Skyway Road
Suite 150
San Carlos, CA 94070
United States
650-260-7120
http://www.iovance.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees63

Key Executives

NameTitlePayExercisedYear Born
Dr. Maria FardisCEO, Pres & Director441.67kN/A1968
Mr. Timothy E. MorrisCFO, Principal Accounting Officer & Corp. Sec.N/AN/A1962
Dr. Frederick G. Vogt Ph.D., Esq.Gen. CounselN/AN/A1974
Mr. Howard B. JohnsonSr. VP of Corp. Devel., Alliance Management & Program ManagementN/AN/A1960
Dr. Elma S. Hawkins Ph.D., MBAAdvisor to the Board465.39kN/A1957
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with PharmaCell B.V and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas M.D. Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

Corporate Governance

Iovance Biotherapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2018 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.